

CURRICULUM VITAE

SAMUEL LEONARD STANLEY, JR., M.D.

PERSONAL INFORMATION

Place of birth: Seattle, Washington
Spouse: Ellen Li, M.D., Ph.D.

CITIZENSHIP: U.S.A.

PRESENT POSITION: Vice Chancellor for Research

EDUCATION:

1976 B.A., Biological Sciences, The College of the University of Chicago, IL
1980 M.D., Medicine, Harvard University Medical School, Cambridge, MA
1984-1987 Post-doctoral, Immunology, Washington University School of Medicine, St. Louis, MO

ACADEMIC POSITIONS/EMPLOYMENT:

1976 Teaching Assistant in Biology, The College of the University of Chicago, IL
1980-1981 Medical Intern, Massachusetts General Hospital, Boston, MA
1981-1983 Medical Resident, Massachusetts General Hospital, Boston, MA
1983-1984 Fellow in Infectious Diseases, Washington University School of Medicine, St. Louis, MO
1985-1988 Pfizer Fellow in Microbiology and Immunology, Washington University School of Medicine, St. Louis, MO
1987-1988 Instructor in Medicine, Washington University School of Medicine, St. Louis, MO
1988 Assistant Professor, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO
1989 Assistant Professor, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO
1990-Present Chief Medical Consultant, BarnesCare Travelers Clinic
1993-1999 Associate Professor (with tenure), Department of Medicine
1994-2004 Associate Professor, Department of Molecular Microbiology
1999-Present Professor, Department of Medicine
2003-Present Director, Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research
2004-Present Professor, Department of Molecular Microbiology
2006-Present Vice Chancellor for Research, Washington University in Saint Louis

UNIVERSITY AND HOSPITAL APPOINTMENTS AND COMMITTEES:

1987- Present Attending physician, Internal Medicine and Infectious Diseases, Barnes-Jewish Hospital of St. Louis
Chief Medical Consultant, BarnesCare Travelers Clinic
1989 Chairman, Committee to formulate a health policy for Washington University Personnel who work with animals.
1992-2000 Member, Washington University MA/MD Committee
1992-2001 Program Committee, American Society of Tropical Medicine and Hygiene
1995-1997 At-large Representative Washington University Faculty Senate
Member, Senate Council of Washington University
Member, Advisory Committee on Academic Freedom and Tenure
1997-1999 Faculty Representative, Washington University Benefits Committee
1999-2004 Selection Committee and Advisory Board Medical Student International Fellowships
2000-2002 Clinical Representative to the Executive Faculty, Washington University School of Medicine

2000-2004 Chairman, Institutional Biological and Chemical Safety Committee
2001-2002 Division of Biology and Biomedical Sciences Graduate Admissions Committee
2006- Chairman, Research Strategic Planning for Washington University School of Medicine
2007- Chairman, Skandalaris Center Research Planning Committee

MEDICAL LICENSURE AND BOARD CERTIFICATION:

Massachusetts License 1980-83
Missouri License 1983-present
American Board of Internal Medicine, Certification in Internal Medicine 1983
American Board of Internal Medicine, Certification in Infectious Diseases 1986

MILITARY SERVICE: None

HONORS:

1976 Honors in Biological Sciences, University of Chicago
1976 Phi Beta Kappa, University of Chicago
1979 Albert Schweitzer Fellow of Harvard Medical School
1985-1988 Pfizer Postdoctoral Fellow
1994-1999 Research Career Development Award, NIH
1999-2004 Burroughs-Wellcome Scholar in Molecular Parasitology
2000 Distinguished Service Teaching Award—Washington University School of Medicine
2002-2004 Permanent member, Tropical Medicine and Parasitology Study Section
2004-2006 Permanent member, Eukaryotic Pathogenesis Study Section
2005-2006 Excellence in Mentoring, Washington University School of Medicine
2006 Distinguished Service Award, Washington University Medical Center Alumni Assn
2007-2008 Ambassador, Paul G. Rogers Society for Global Health Research

COMMUNITY AND REGIONAL RESPONSIBILITIES:

2006- Board of Directors, Center for Emerging Technologies
2006- Board Member, Research Alliance of Missouri
2006- Board of Trustees, Saint Louis Academy of Science
2007- Board Member, St. Louis Center of Excellence, Missouri Life Sciences Trust Fund

EDITORIAL and REVIEW RESPONSIBILITIES:

Editorial Board: Infection and Immunity 1998-2003

Ad hoc reviewer for:

New England Journal of Medicine	Vaccine
Clinical Infectious Diseases	Parasite Immunology
Journal of Infectious Diseases	Experimental Parasitology
Molecular Microbiology	Lancet
Gastroenterology	Journal of Parasitology
Physiological Reviews	Am.J.Tropical Medicine and Hygiene
Cellular Microbiology	Laboratory Animal Science
PNAS	Molecular and Biochemical Parasitology
Acta Tropica	Nature

Ad hoc grant reviewer for:

Wellcome Trust
International Center for Diarrhoeal Disease Research
USAID
American Federation for AIDS Research
NIH—SEPs on TDRU program

Temporary member: NIH-TMP study section 10-2000, 6-2002
EpScor NSF Site Visit Team 2005

NATIONAL PANELS

National Science Advisory Board for Biosecurity (NSABB), Criteria Roundtable Adviser 6/2006
NIH Blue Ribbon Panel on the New England Infectious Diseases Research Laboratory 2008-
NIH National Advisory Allergy & Infectious Diseases Council 2008 - 2012
U.S. Department of Commerce, Emerging Technology and Research Advisory Committee 2008 -

PROFESSIONAL SOCIETIES AND ORGANIZATIONS:

Associate Member American College of Physicians, 1981
Member, Infectious Disease Society of America, 1989
Member, American Society of Tropical Medicine and Hygiene, 1988
Member, American Federation for Clinical Research, 1989
Member, American Society for Microbiology, 1992
Fellow, Infectious Disease Society of America, 1995
Member, American Society for Clinical Investigation, 1995
Secretary-Treasurer, Board of Directors, Infectious Diseases Society of St. Louis, 2004-2007

MAJOR INVITED LECTURES:

Visiting scientist and lecturer—Centro de Investigacion y de Estudios Avanzados del IPN, Mexico City, Mexico 3/91
"Molecular approach to *Entamoeba histolytica* pathogenesis", St. Louis University 4/91.
Chair—Amebiasis Session, American Society Tropical Medicine Hygiene—"Isolation of an *Entamoeba histolytica* cDNA clone encoding a protein with a zinc finger domain." Boston, 11/91.
Keynote Speaker—"Role of the amebic cysteine proteinase in amebic liver abscess formation". Meeting of the Society of Biological Chemistry (Mexico), Zacatecas, Mexico, 11/94.
Co-chair and Speaker—Merck Symposium on Amebiasis—"New models for amebiasis". ASTMH Meetings, Cincinnati. 11/94
Speaker—"Scid mouse model of amebiasis" and "Scid mice and gene knockout mice as models for parasitic disease". India/U.S.A. Joint Vaccine Action Program, Lucknow, India. 12/94.
Speaker—"What can murine models tell us about the immunobiology of amebiasis?" Berne Immunology Center, U. of Va., Charlottesville. 12/94
Speaker—"Progress in a vaccine for amebiasis.", Eur. Conf. Trop. Med., Hamburg, 11/95
Chair and Speaker—Symposium--New insights into the immunobiology of parasitic diseases from knockout and scid mice. ASTMH Meeting, 12/96.
Speaker—Bernardo Sepulveda Molecular Biology Seminar, XIII Congress on Amebiasis, Mexico City, Mexico. 1/97
Speaker—Keystone Symposium on Cellular and Molecular Cross Talk at Mucosal Surfaces, Santa Fe, New Mexico 3/97.
Speaker—"EhADH2 enzyme: A novel target for anti-amebic drugs". ICTDR Conference, Washington, D.C., 4/97.
Speaker—"Oral and DNA vaccines to prevent amebiasis." ICTDR Conference, Washington, D.C., 4/98.
Speaker—"How intestinal epithelial cells regulate the inflammatory response to enteric pathogens". U.T. Health Sciences Center, San Antonio, TX. 6/98
Visiting professor and speaker—"Amebiasis: Putting man into mouse to understand an ancient enemy." NYU Medical Center Grand Rounds. 1/99
Speaker—"Pathways for amebic induction of inflammation and programmed cell death", Burroughs Wellcome Symposium, ASTMH Meeting, Washington, D.C., 11/99.
Speaker—"Pathways for amoebic induction of inflammation and tissue damage." International Symposium on Amoebiasis. Hamburg, Germany, 7/2000.
Speaker—National Institutes of Health/National Institute for Allergic and Infectious Diseases "Amebic dysentery and ICE." 4/2001.
Speaker—St. Louis University "Amebic dysentery and ICE 9/2001

Speaker—U.T. El Paso “Amebic dysentery and ICE” 10/2001

Speaker—Southern Illinois University at Carbondale “Amebic dysentery and ICE”, 10/2001.

Speaker—Washington University School of Medicine, Department of Pediatrics Grand Rounds, “Amebiasis—new insights into an ancient enemy” 10/2001

Chairman, and speaker: Session on Amebiasis: Ellison Foundation Conference on Tropical Diseases, Bhubaneswar, India, Feb. 2002

Speaker—Woods Hole Tropical Medicine and Parasitology Course: “Amebiasis”, July 2002, July 2003.

Speaker—Plenary Session, X International Conference on Parasitology, Vancouver, B.C. “Pathways for amebic induction of inflammation and programmed cell death. Aug. 2002.

Speaker—Special Symposium in Honor of Jean Hickman. ASTMH meeting Denver. “New insights into amebiasis from SCID-HU-INT mice. Nov. 2002

Speaker—EMBO Conference on Amebiasis, Paris, France “Role of TNF in amebic induced inflammation”. Mar. 2003

Speaker—Engineering Connections Series—“SARS and other emerging infectious diseases—the dangers of a small world”. Washington University Sept. 2003

Speaker—Yonsei University—Challenges in the Post Genomic Era—“Simultaneous host/pathogen genomics.” Nov. 2003.

Speaker—Korean Society of Parasitology—Pathways for amebic induction of inflammation and and programmed cell death. Nov. 2003.

Speaker—Institute Pasteur—“New insights into dysentery from SCID-HU-INT mice”. Nov 2003.

Speaker—University of Illinois, Emerging Infectious Diseases Conference “Pathogenesis of amebiasis”. Mar.2004.

Speaker—University of Pennsylvania, Parasitology Group: “Understanding amebiasis from the host and pathogen perspective. Nov. 2004

Speaker—Washington University School of Medicine, Medical Grand Rounds: “Emerging Infectious Diseases—Preparing for the Unexpected and the Inevitable”. Nov. 2004

Speaker—7th Annual Conference on Hemophilia—San Juan Puerto Rico, Emerging Infections —Preparing for the unexpected and the inevitable. Feb. 2005

Speaker—NIAID/NIDDK workshop on Humanized Mouse Models of Disease. Washington, DC.

Speaker—ASM Biodefense Meeting, Washington D.C., : "Chimeric SCID-Human Mice to Study Enteric Pathogens." Feb. 2006

Speaker—MMI/ID Seminar Series: "Molecular Dissection of *Entamoeba Histolytica* Pathogenesis." Mar. 2006

Speaker—Washington University Reunion Medical Update: "Avian Influenza & Emerging Infectious Diseases." May, 2006.

Speaker—Washington University Reunion College: "The Threat of Emerging Infectious Diseases, Avian Influenza and Beyond." May, 2006

Speaker—Pathobiology of human diseases series: Biodefense and the immunogenetics of smallpox vaccination. Washington University, May 2007.

Speaker—IGCC-Public Policy and Biological Threats: Training the Next Generation; “*Basics of Viral Pathogenesis and Disease.*” La Jolla, CA, July 2007.

Speaker—13th Annual Kentucky EPSCoR Statewide Conference. “Perspectives and lessons-learned in building academic team science.” Lexington, KY, October 2007.

Speaker—5th Annual MRCE Meeting, Washington University. “Immunogenetics of Smallpox Vaccination.” St. Louis, MO, October 2007.

Speaker—IGCC-Public Policy and Biological Threats: Training the Next Generation; “*Basics of Viral Pathogenesis and Disease.*” La Jolla, CA, July 2008.

Speaker—Institute for Public Health, *International Public Health Activities at Washington University in St. Louis*; Washington University, September 2008.

Speaker—Tradeline, Inc., Academic Medical & Health Science Centers 2008; “*Key program and facility initiatives to grow disease-focused research and funding.*” San Francisco, CA, October 2008.

RESEARCH SUPPORT:

Principal Investigator, U54 AI057160-01, “Midwest Regional Center for Excellence in Biodefense and Emerging Infectious Diseases Research, 9/1/03 to 3/1/14, Direct costs: \$5,123,000/yr.

Principal Investigator, NIAID R01 AI-30084, "Molecular Dissection of *Entamoeba histolytica* pathogenesis." 7/01/95 to 1/31/2011. Current year direct costs: \$250,000

Co-Investigator, 1UL1RR024992-01 (Kenneth Polonsky, M.D. Principal Investigator) Washington University Institute of Clinical and Translational Sciences (CTSA), Co-Director, Tracking and Evaluation Program. 9/17/07 to 5/31/12, Current year funds \$6,818,890.

Principal Investigator, Pathways of inflammation and tissue damage in amebiasis. Burroughs Wellcome Scholar in Molecular Parasitology. 7/1/99 to 6/30/06, Total direct costs: \$425,000.00

Principal Investigator, NIAID R01 AI-51621-01 "Structure-Function of *Entamoeba* alcohol dehydrogenase 2". 5/01/02 to 3/31/06, Direct costs \$200,000/yr.

CLINICAL TITLE AND RESPONSIBILITIES:

Attending physician, Red Medical Service, Barnes Hospital, 1989 to 2007.
Attending physician, Infectious Diseases Service, Barnes-Jewish Hospital, 1987 to 2007.
Chief Medical Consultant, BarnesCare Travelers Clinic, 1990 to present.

TEACHING TITLE AND RESPONSIBILITIES:

Lecturer, Washington University School of Medicine, 1st Year Course in Microbiology "Introduction to Tropical Medicine".
Lecturer, Washington University School of Medicine, 2nd Year Course in Pathophysiology of Infectious Diseases "Bacteremia and Sepsis" and "Protozoa I, Protozoa III" "Cases in Tropical Medicine"
Lecturer, Infectious Diseases and the Diagnostic Laboratory Course, "Intestinal Protozoa".
Lecturer, Clinical Infectious Diseases Course, "Diarrheal Diseases", "Diseases of Travelers", and "Bacteremia and Sepsis", "Tropical Diseases".
Lecturer, Lucille P. Markey Special Emphasis Pathway in Human Pathobiology, "Vaccines for Malaria".
Lecturer, Microbial Pathogenesis Course, "MDR genes and pathogenesis".
Lecturer, Molecular Mechanisms of Disease Course, "Vaccines against parasitic diseases".
Instructor, Case Problems in Cell Biology and Biochemistry
Instructor, Tropical Medicine Course
Faculty advisor: International Health and Tropical Medicine Forum
Lecturer, Barnes Housestaff Conference, "Diseases of Travelers".
Lecturer, Microbiology 1st year Graduate Student Course: "Protozoan taxonomy and diversity"

PUBLICATIONS:

PEER-REVIEWED

Wong, YC; **Stanley Jr, SL**; Garber, BB. Separation and characterization of neuronal and glial cell populations from embryonic chick cerebra in culture. *Anatomischer Anzeiger*, 1981; 150:351-373.

Stanley Jr, SL; Kehl, O. Ascending paralysis associated with diethylcarbamazine treatment of a *M. loa loa* infestation--A case report and review of the literature. *Tropical Doctor*, 1982; 12:16-19.

Stanley Jr, SL; Lusk, R. Thoracic actinomycosis presenting as a brachial plexus syndrome. *Thorax*, 1985; 40:74-75.

Powderly, WG; **Stanley Jr, SL**; Medoff, G. Pneumococcal endocarditis: Report of a series and review of the literature. *Review of Infectious Diseases*, 1986; 8:786-789.

Stanley Jr, SL; Bischoff, JK; Davie, JM. Antigen induced rheumatoid factors: Protein and carbohydrate

antigens induce different rheumatoid factor responses. *Journal of Immunology*, 1987; 139:2936-2942.

Stanley Jr, SL; Li, E; Davie, JM. Antigen induced rheumatoid factors: Characterization of monoclonal rheumatoid factors produced after protein and carbohydrate immunization. *Molecular Immunology*, 1988; 25:285-291.

Li, E; Becker, A; **Stanley Jr, SL**. Use of Chinese hamster ovary cells with altered glycosylation patterns to define the carbohydrate specificity of *Entamoeba histolytica* adhesion. *Journal of Experimental Medicine*, 1988, May; 167(5):1725-1730.

Li, E; Becker, A; **Stanley Jr, SL**. Chinese hamster ovary cells deficient in N-acetylglucosaminyltransferase I activity are resistant to *Entamoeba histolytica*-mediated cytotoxicity. *Infection & Immunity*, 1989; 57:8-12.

Stanley Jr, SL; Becker, A; Kunz-Jenkins, C; Foster, L; Li, E. Cloning and expression of a membrane antigen of *Entamoeba histolytica* possessing multiple tandem repeats. *Proceedings of the National Academy of Sciences of the USA*, 1990, Jul 1; 87(13):4976-4980.

Burch, DJ; Li, E; Reed, S; Jackson, TFHG; **Stanley Jr, SL**. Isolation of a strain-specific *Entamoeba histolytica* cDNA clone. *Journal of Clinical Microbiology*, 1991; 29:696-701.

Stanley Jr, SL; Jackson, TFHG; Reed, SL; Calderon, J; Kunz-Jenkins, C; Gathiram, V; Li, E. Serodiagnosis of invasive amebiasis using a recombinant *Entamoeba histolytica* protein. *JAMA*, 1991, Oct; 266(14):1984-1986.

Stanley Jr, SL; Foster, L; Phillips, N. Molecular analysis of carbohydrate antigen induced monoclonal IgM anti-IgG antibodies (rheumatoid factors). *Molecular Immunology*, 1992, Apr; 29(4):453-61.

Stanley Jr, SL; Huizenga, H; Li, E. Isolation and partial characterization of a surface glycoconjugate of *Entamoeba histolytica*. *Molecular & Biochemical Parasitology*, 1992; 50:127-138.

Stanley Jr, SL; Li, E. Isolation of an *Entamoeba histolytica* cDNA clone encoding a protein with a putative zinc finger domain. *Molecular & Biochemical Parasitology*, 1992; 50:185-188.

Li, E; Kunz-Jenkins, C; **Stanley Jr, SL**. Isolation and characterization of genomic clones encoding a serine-rich *Entamoeba histolytica* protein. *Molecular & Biochemical Parasitology*, 1992; 50:355-358.

Cieslak, PR; **Stanley Jr, SL**. Advances in amebiasis: implications for the clinician. *Infectious Diseases in Clinical Practice*, 1992; 1(3):151-157.

Zhang, Y; Li, E; Jackson, TFHG; Zhang, T; Gathiram, V; **Stanley Jr, SL**. Use of a recombinant 170 kDa surface antigen of *Entamoeba histolytica* in serodiagnosis of amebiasis, and identification of immunodominant domains of the native molecule. *Journal of Clinical Microbiology*, 1992, Nov; 30(11):2788-2792.

Cieslak, PR; Virgin IV, HW; **Stanley Jr, SL**. A severe combined immunodeficient (SCID) mouse model for infection with *Entamoeba histolytica*. *Journal of Experimental Medicine*, 1992, Dec; 176(6):1605-1609.

Myung, K; Burch, DJ; Jackson, TFHG; **Stanley Jr, SL**. Serodiagnosis of invasive amebiasis using a recombinant *Entamoeba histolytica*-antigen based ELISA. *Archives of Medical Research*, 1992; 23(2):285-288.

Zhang, Y; Aley, S; **Stanley Jr, SL**; Gillin, FD. Cysteine-dependent zinc binding by membrane proteins of *Giardia lamblia*. *Infection & Immunity*, 1993; 61:520-524.

- Cieslak, PR; Zhang, T; **Stanley Jr, SL**. Expression of a recombinant *Entamoeba histolytica* antigen in a *Salmonella typhimurium* vaccine strain. *Vaccine*, 1993; 11:773-776.
- Zhang, Y; Li, E; **Stanley Jr, SL**. *Entamoeba histolytica*: The EHZc3 cDNA clone encodes a zinc-binding protein. *Experimental Parasitology*, 1993, Aug; 77(1):118-120.
- Zhang, T; Cieslak, PR; Foster, L; Kunz-Jenkins, C; **Stanley Jr, SL**. Antibodies to the serine rich *Entamoeba histolytica* protein (SREHP) prevent amebic liver abscess in severe combined immunodeficient (SCID) mice. *Parasite Immunology*, 1994, May; 16(5):225-230.
- Zhang, T; Cieslak, PR; **Stanley Jr, SL**. Protection of gerbils from amebic liver abscess by immunization with a recombinant *Entamoeba histolytica* antigen. *Infection & Immunity*, 1994, Apr; 62(4):1166-70.
- Yang, W; Li, E; Kairong, T; **Stanley Jr, SL**. *Entamoeba histolytica* has an alcohol dehydrogenase homologous to the *adhE* gene product of *Escherichia coli*. *Molecular & Biochemical Parasitology*, 1994; 64:253-260.
- Zhang, T; **Stanley Jr, SL**. Protection of gerbils from amebic liver abscess by immunization with a recombinant protein derived from the 170 kDa adhesin of *Entamoeba histolytica*. *Infection & Immunity*, 1994; 62(6):2605-2608.
- Li, E; Stenson, WF; Kunz-Jenkins, C; Swanson, PE; Duncan, R; **Stanley Jr, SL**. *Entamoeba histolytica* interactions with polarized human intestinal Caco-2 epithelial cells. *Infection & Immunity*, 1994; 64(11):5112-5119.
- Stanley Jr, SL**; Tian, K; Koester, JP; Li, E. The serine rich *Entamoeba histolytica* protein (SREHP) is a phosphorylated membrane protein containing O-linked terminal N-acetylglucosamine (O-GlcNAc) residues. *Journal of Biological Chemistry*, 1995, Feb; 270(8):4121-4126.
- Stanley Jr, SL**; Blanchard, JL; Johnson, N; Foster, L; Kunz-Jenkins, C; Zhang, T; Tian, K; Cogswell, FB. Immunogenicity of the recombinant serine rich *Entamoeba histolytica* protein (SREHP) amebiasis vaccine in the African Green Monkey. *Vaccine*, 1995, Jul; 13(10):947-951.
- Zhang, T; Li, E; **Stanley Jr, SL**. Oral immunization with the dodecapeptide repeat of the serine rich *Entamoeba histolytica* protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response. *Infection & Immunity*. 1995, Apr; 63(4):1349-1355.
- Stanley Jr, SL**; Zhang, T; Rubin, D; Li, E. Role of the amebic cysteine proteinase in amebic liver abscess in severe combined immunodeficient (SCID) mice. *Infection & Immunity*, 1995, Apr; 63(4):1587-1590.
- Velazquez, C; Valette, I; Cruz, M; Labra, M-L; Montes, J; **Stanley Jr, SL**; Calderon, J. Identification of immunogenic epitopes of the 170-kDa subunit adhesin of *Entamoeba histolytica* in patients with invasive amebiasis. *Journal of Eukaryotic Microbiology*, 1995, Sep; 42(5):636-641.
- Li, E; Yang, W-G; Zhang, T; **Stanley Jr, SL**. Interaction of laminin with *Entamoeba histolytica* cysteine proteinases and its effect on amebic pathogenesis. *Infection & Immunity*. 1995, Oct; 63(10):4150-4153.
- Flores, BM; **Stanley Jr, SL**; Yong, TS; Ali, M; Diedrich, DL; Torian, BE. Surface localization, regulation, and biologic properties of the 96-kDa alcohol/aldehyde dehydrogenase (EhADH2) of pathogenic *Entamoeba histolytica*. *Journal of Infectious Diseases*, 1996, Jan; 173(1):226-231.
- Yong, TS; Li, E; Clark, D; **Stanley Jr, SL**. Complementation of a *Escherichia coli adhE* mutant by the *Entamoeba histolytica EhADH2* gene provides a method for the identification of new anti-amebic drugs. *Proceedings of the National Academy of Sciences of the USA*, 1996, Jun 25; 93(13):6464-6469.

- Seydel, KB; Braun, K; Zhang, T; Jackson, TFHG; **Stanley Jr, SL**. Human anti-amebic antibodies provide protection against amebic liver abscess formation in the SCID mouse. *The American Journal of Tropical Medicine & Hygiene*, 1996; 55:330-332.
- Zhang, T; **Stanley Jr, SL**. Oral immunization with an attenuated vaccine strain of *Salmonella typhimurium* expressing the serine rich *Entamoeba histolytica* protein induces an anti-amebic immune response and protects gerbils from amebic liver disease. *Infection & Immunity*, 1996, May; 64(5):1526-1531.
- Seydel, KB; Li, E; **Stanley Jr, SL**. Human intestinal epithelial cells produce pro-inflammatory cytokines in response to infection in a SCID-HU-INT model of amebiasis. *Infection & Immunity*, 1997, May; 65(5):1631-1639.
- Lotter, H; Zhang, T; Seydel, KB; **Stanley Jr, SL**; Tannich, E. Identification of an epitope on the *Entamoeba histolytica* 170 kDa-lectin conferring antibody mediated protection against invasive amebiasis. *Journal of Experimental Medicine*, 1997, May 19 185(10):1793-1801.
- Ryan, ET; Butterson, JR; Zhang, T; **Stanley Jr, SL**; Calderwood, SB. Oral immunization with attenuated vaccine strains of *Vibrio cholerae* expressing a dodecapeptide repeat of the serine rich *Entamoeba histolytica* protein fused to the cholera toxin B subunit induces systemic and mucosal anti-amebic and anti-*V. cholerae* antibody responses in mice. *Infection & Immunity*, 1997, Aug; 65(8):3118-3125.
- Seydel, KB; Zhang, T; **Stanley Jr, SL**. Neutrophils play a critical role in early resistance to amebic liver abscess in SCID mice. *Infection & Immunity*, 1997, Sep; 65(9):3951-3953.
- Zhang, T; **Stanley Jr, SL** Expression of the serine rich *Entamoeba histolytica* protein (SREHP) in the avirulent vaccine strain *Salmonella typhi* TY2₄₂₉₇ Δ *cytA* Δ *crp* Δ *asd*: Safety and immunogenicity in mice. *Vaccine*, 1997, Aug-Sep; 15(12-13): 1319-1322.
- Marinets, A; Zhang, T; Guillen, N; Gounon, P; Bohle, B; Vollman, U; Scheiner, O; Wiedermann, G; **Stanley Jr, SL**; Duchene, M. Protection against invasive amoebiasis by a single monoclonal antibody directed against a lipophosphoglycan antigen localized on the surface of *Entamoeba histolytica*. *Journal of Experimental Medicine*, 1997; 186:1557-1565.
- Wang, L; Calderon, J; **Stanley Jr, SL**. Identification of B cell epitopes in the serine rich *Entamoeba histolytica* protein. *The American Journal of Tropical Medicine & Hygiene*, 1997, Dec; 57(6):723-726.
- Stanley Jr, SL**; Jackson, TFHG; Foster, L; Singh, S. Longitudinal study of the antibody response to recombinant *Entamoeba histolytica* antigens in patients with amebic liver abscess. *The American Journal of Tropical Medicine & Hygiene*, 1998, Apr; 58(4):414-416.
- Sultan, F; Jin-L-I; Jobling, MG; Holmes, RK; **Stanley Jr, SL** Mucosal immunogenicity of a holotoxin-like molecule containing the serine rich *Entamoeba histolytica* protein (SREHP) fused to the A₂ domain of cholera toxin. *Infection & Immunity*, 1998, Feb; 66(2):462-468.
- Seydel, KB; Zhang, T; Champion, GA; Fichtenbaum, C; Swanson, PE; Tzipori, S; Griffiths, JK; **Stanley Jr, SL**. *Cryptosporidium parvum* infection induces human TNF α and IL-8 production from human intestinal xenografts in SCID mice. *Infection & Immunity*, 1998; 66:2379-2398.
- Seydel, KB; **Stanley Jr, SL**. *Entamoeba histolytica* induces host cell death in amebic liver abscess by a non-Fas, non-TNF α -dependent pathway of apoptosis. *Infection & Immunity*, 1998 Jun; 66(6):2980-2983.
- Seydel, KB; Li, E; Zhang, Z; **Stanley Jr, SL**. Epithelial cell-initiated inflammation plays a crucial role in early tissue damage in amebic infection of human intestine. *Gastroenterology*, 1998, Dec; 115(6):1446-

Temesvari, LA.; Harris, EN; **Stanley Jr, SL**; Cardelli, JA. Early and late endosomal compartments of *Entamoeba histolytica* are enriched in cysteine proteinases, acid phosphatases and several Ras-related Rab GTPases. *Molecular & Biochemical Parasitology*, 1999; 103:225-241.

Zhang, T; **Stanley Jr, SL**. DNA vaccination with the serine rich *Entamoeba histolytica* protein (SREHP) prevents amebic liver abscess in rodent models of disease. *Vaccine*, 1999, Dec 10; 18(9-10):868-874.

Seydel, KB; Smith, SJ; **Stanley Jr, SL**. Interferon-gamma and nitric oxide are required for host defense in a murine model of amebic liver abscess. *Infection & Immunity*, 2000; 68:400-402.

Lotter, H; Khajawa, F; **Stanley Jr, SL**; Tannich, E. Protection of gerbils from amebic liver abscess by vaccination with a 25 mer peptide derived from the "cysteine-rich" region of the *Entamoeba histolytica* galactose-specific adherence lectin. *Infection & Immunity*, 2000; 68:4416-4421.

Zhang, Z; Yan, L; Wang, L; Seydel, KB; Li, E; Ankri, S; Mirelman, D; **Stanley Jr, SL**. *Entamoeba histolytica* cysteine proteinases with interleukin-1 beta converting enzyme (ICE) activity cause intestinal inflammation and tissue damage in amebiasis. *Molecular Microbiology*, 2000, Aug; 37(3):542-548.

Zhang, Z; Jin, L; Champion, G; Seydel, KB; **Stanley Jr, SL**. Shigella infection in SCID-HU-INT mice: role for neutrophils in containing bacterial dissemination in human intestine. *Infection & Immunity*, 2001; 69:3240-3247.

Stenson, W; Zhang, Z; Riehl, T; **Stanley Jr, SL**. Amebic infection induces cyclooxygenase-2 (COX-2) production in human intestine. *Infection & Immunity*, 2001; 69:3382-3388.

Espinosa, A; Yan, L; Zhang, Z; Foster, L; Clark, D; Li, E; **Stanley Jr, SL**. The bifunctional *Entamoeba histolytica* alcohol dehydrogenase 2 (EhADH2) protein is necessary for amebic growth and survival and requires an intact C-terminal domain for both alcohol dehydrogenase and acetaldehyde dehydrogenase activity. *Journal of Biological Chemistry*, 2001, Jun 8; 276(23): 20136-20143.

Babcock, HM; Ritchie, DJ; Christiansen, E; Starlin, R; Little, R; **Stanley Jr, SL**. Successful treatment of vancomycin-resistant *Enterococcus* endocarditis with oral linezolid. *Clinical Infectious Diseases*, 2001, May 1; 32(9):1373-1375.

Yan, L; **Stanley Jr, SL**. Blockade of caspases inhibits amebic liver abscess formation in a mouse model of disease. *Infection & Immunity*, 2001; 69:7911-7914.

Zhang, Z; Duchene, M; **Stanley Jr, SL**. A monoclonal antibody to the amebic lipophosphoglycan/proteophosphoglycan antigens can prevent disease in human intestinal xenografts infected with *Entamoeba histolytica*. *Infection & Immunity*, 2002; 70:5873-5876.

Zhang, Z; Mahajan, S; Zhang, X-C; **Stanley Jr, SL**. Tumor necrosis factor- α is a key mediator of the gut inflammation seen in amebic colitis in human intestine in the SCID mouse-human intestinal xenograft model of disease. *Infection & Immunity*, 2003; 71:5355-5359.

Zhang, X-C; Zhang, Z; Alexander D; Bracha, R; Mirelman, D; **Stanley Jr, SL**. Expression of amoebapores is required for full expression of *Entamoeba histolytica* virulence in amebic liver abscess, but is not necessary for the induction of inflammation or tissue damage in amebic colitis. *Infection & Immunity*, 2004; 72:678-683.

Zhang, Z; **Stanley Jr, SL**. Stereotypic and specific elements of the human colonic response to *Entamoeba histolytica* and *Shigella flexneri* infection. *Cellular Microbiology*, 2004, Jun; 6(6):535-564.

Espinosa, A; Clark, DC; **Stanley Jr, SL**. *Entamoeba histolytica* Alcohol Dehydrogenase 2 (EhADH2) as a target for antiamebic agents. *Journal of Antimicrobial Chemotherapy*, 2004, Jul; 54(1):56-59.

Chen, M; Li, E; **Stanley Jr, SL**. Structural analysis of the acetaldehyde dehydrogenase activity of *Entamoeba histolytica* alcohol dehydrogenase 2 (EhADH2), a member of the ADHE enzyme family. *Molecular & Biochemical Parasitology*, 2004; 137:201-205.

Davis, PH; Zhang, Z; Chen, M; Zhang, XC; Chakraborty, S; **Stanley Jr, SL**. Identification and characterization of a family of Bsp-A like surface proteins of *Entamoeba histolytica* with novel leucine rich repeats. *Molecular & Biochemical Parasitology*, 2006; 145:111-116.

Pelosoff, L; Davis, PH; Zhang, Z; Zhang, XC; **Stanley Jr, SL**. Coordinate but disproportionate activation of apoptotic, regenerative, and inflammatory pathways characterizes the liver response to acute amebic infection. *Cellular Microbiology*, 2006, Mar; 8(3):508-522.

Stanley Jr, SL. The need for continuing vigilance: addressing the threat for transmission of blood-borne infectious disease. *Seminars in Hematology*, 2006, Apr; 43(3) Supplement: S17-S22.

Davis, P; Zhang, X; Guo, J; Townsend, RR; **Stanley Jr, SL**. Comparative proteomic analysis of two *Entamoeba histolytica* stains with different virulence phenotypes identifies peroxiredoxin as an important component of amebic virulence. *Molecular Microbiology*, 2006; 61:1523-1532.

Ludlam, CA; Powderly, WG; Bozzett, S; Diamond, M; Koerper, MA; Kulkarni, R; Ritchie, B; Siegel, J; Simmonds, P; **Stanley Jr, SL**; Tapper, ML; von Depka, M. Clinical perspectives of emerging pathogens in bleeding disorders. *Lancet*, 2006, Jan 21; 367(9506):252-261.

Davis, PA; Schulz, J; **Stanley Jr, SL**. Transcriptomic comparison of two *Entamoeba histolytica* stains with defined virulence phenotypes identifies new virulence factor candidates and key differences in the expression patterns of cysteine proteases, lectin light chains, and calmodulin. *Molecular & Biochemical Parasitology*, 2007, Jan; 151(1):118-128.

Stanley Jr, SL; Frey, SE; Taillon-Miller, P; Guo, J; Miller RD; Koboldt, DC; Elashoff, M; Christensen, R; Saccone, NL; Belshe, RB. The Immunogenetics of Smallpox Vaccination. *Journal of Infectious Diseases*, 2007, Jul 15; 196(2): 212-219.

Lawrence, SJ; Lottenbach, KR; Newman, FK; Buller, RM; Bellone, CJ; Chen, JJ; Cohen, GH; Eisenberg, RJ; Belshe, RB; **Stanley Jr, SL**; Frey, SE. Antibody response to vaccinia membrane proteins after smallpox vaccination. *Journal of Infectious Diseases*, 2007; 196(2):220-229.

Melendez-Lopez SG; Herdman, S; Hirata K; Choi, MH; Choe, Y; Craik, C; Caffrey, CR; Hansell, E; Chavez-Munguia, B; Chen, YT; Roush, WR; Mckerrow, J; Eckmann, L; Guo, J; **Stanley Jr, SL**; Reed, SL. Use of recombinant *Entamoeba histolytica* cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model. *Eukaryotic Cell*, 2007, Jul; 6(7):1130-1136.

Bullok, KE; Maxwell, D; Kesarwala, AH; Gammon, S; Prior, JL; Snow, M; **Stanley, S**; Piwnicka-Worms, D. Biochemical and in vivo characterization of a small membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. *Biochemistry*, 2007, Apr 3; 46 (13): 4055-4065.

Snow, M; Chen, M; Guo, J; Atkinson, J; **Stanley Jr, SL**. Differences in complement mediated killing of *Entamoeba histolytica* between men and women—an explanation for the increased susceptibility of men to invasive amebiasis? *American Journal of Tropical Medicine and Hygiene*. 2008, June; 78 (6): 922-923.

Sarder, P; Nehorai, A; Davis, PH; **Stanley Jr, SL**. Estimating gene signals from noisy microarray images. *IEEE Transactions on NanoBioscience*. 2008, June, 7(2):142-153.

Sperandio, B., Regnault B., Guo J., Zhang Z, **Stanley SL Jr.**, Sansonetti PJ, Pedron T. Virulent *Shigella flexneri* subverts the host innate immune response through the manipulation of antimicrobial peptide gene expression. *Journal of Experimental Medicine*, 2008, 205:1121-32.

REVIEWS AND INVITED PUBLICATIONS:

Stanley Jr, SL; Davie, JM. "Production and function of rheumatoid factors in the normal immune response" *Contribution to Microbiology Immunology*, 1989; 11:151-187.

Li, E; **Stanley Jr, SL**. "The role of newer antibiotics in gastroenterology." *Gastroenterology Clinics of North America*, 1992; 21: 613-631.

Stanley Jr, SL; Burch, DJ; Cieslak, P. "New diagnostic techniques in amebiasis." *LabMedica International* 1992; 9:7-10.

Stanley Jr, SL. "Amebiasis", in *Conn's Current Therapy*." R.E. Rakel, Ed. W.B. Saunders Company, Philadelphia, pp. 60-62, 1993.

Stanley Jr, SL; Li, E. "Pathophysiology of Amebiasis." *Seminars in Gastrointestinal Disease* 1993; 4:214-223.

Stanley Jr, SL; Virgin, IV, HW. "Scid mice as models for helminth and protozoan diseases." *Parasitology Today* 1993; 9:406-412.

Stanley Jr, SL. "Susceptibility testing and acquired drug resistance in parasitic diseases", in *Handbook of Clinical Microbiology*, Washington, DC, P. R. Murray, Ed. ASM Press. pp. 1424-1427, 1995.

Li, E; **Stanley Jr, SL**. "Parasitic diseases of the GI tract." *Current Opinion in Gastroenterology*, 1995; 11:63-68.

Li, E; **Stanley Jr, SL**. "Amebiasis." *Gastroenterology Clinics of North America*, 1996; 25:471-492.

Seydel, K; **Stanley Jr, SL**. "Scid mouse models for parasitic diseases." *Clinical Microbiology Review*, 1996; 9:126-134.

Stanley Jr, SL. "Progress in a vaccine for amebiasis." *Parasitology Today*. 1996; 12:7-14.

Sultan, F; **Stanley Jr, SL**. "Amebiasis" in *Current Diagnosis* 9, edited by Conn, RB, Borer, WZ, and Snyder, JW. Philadelphia, W.B. Saunders, pp. 225-227, 1997.

Stanley Jr, SL. "Progress towards development of a vaccine for amebiasis." *Clinical Microbiology Review*, 1997, Oct; 10(4):637-649.

Stanley Jr, SL. "Malaria vaccines: Are seven antigens better than one?" *Lancet* 352 (9135):1163-1164), 1998.

Stanley Jr, SL. "Advice to travelers" in *Textbook of Gastroenterology*, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 1145-1159, 1999.

Stanley Jr, SL. "Advice to travelers" in *Atlas of Gastroenterology*, 2nd Edition, edited by Yamada, T.

Philadelphia, Lippincott-Raven, pp. 127-138, 1999.

Li, E; **Stanley Jr, SL.** “Parasitic diseases—protozoa” in *Textbook of Gastroenterology*, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 2423-2441, 1999.

Li, E; **Stanley Jr, SL.** “Parasitic diseases—protozoa” in *Atlas of Gastroenterology*, 2nd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 516-526, 1999.

Stanley Jr, SL. “Prevention of amebiasis and potential of new interventions.” In *Amebiasis*, edited by Ravdin, J.I. London, Imperial College Press, pp. 137-163, 2000.

Stanley Jr, SL; Zhang, T; Seydel, KB. “Animal models of amebiasis.” In *Handbook of Animal Models of Infection*, edited by Zak, O, and Sande, M. London, Academic Press, pp. 859-865, 2000.

Stanley Jr, SL. “Extraintestinal amebiasis.” In *Current Therapy for Infectious Diseases*, Edited by Schlossberg, D., St. Louis, Mosby, Inc. pp. 693-695, 2001.

Stanley Jr, SL; Li, E. “Amoebiasis.” In *Encyclopedia of Life Sciences*. London, Macmillan Reference Limited. 2001

Stanley Jr, SL. “Pathophysiology of amebiasis.” *Trends in Parasitology*, (formerly Parasitology Today). 2001; 17:280-285.

Stanley Jr, SL; Reed, SL. “*Entamoeba histolytica*: parasite-host interactions.” *American Journal of Physiology – Gastrointestinal & Liver Physiology*. 2001, Jun; 280: G1049-G1054.

Stanley Jr, SL. “Protective immunity to amebiasis: New insights and new challenges.” *Journal of Infectious Diseases*, 2001; 184:504-506.

Stanley Jr, SL. “Amebiasis.” *Pier Module*. 2002. www.pier

Stanley Jr, SL. “Pathways for amebic induction of inflammation and programmed cell death.” *Journal of Parasitology*, 2003; 89:S182-S188.

Stanley Jr, SL. “Amoebiasis.” *Lancet*, 2003. 361:1025-34.

Stanley Jr, SL. “Advice to travelers” in *Textbook of Gastroenterology*, 4th Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 1120-1134, 2003.

Stanley Jr, SL. “Advice to travelers” in *Atlas of Gastroenterology*, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 153-162, 2003.

Li, E; **Stanley Jr, SL.** “Parasitic diseases—protozoa” in *Textbook of Gastroenterology*, 4th Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven . pp. 2589-2607, 2003.

Li, E; **Stanley Jr, SL.** “Parasitic diseases—protozoa” in *Atlas of Gastroenterology*, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 749-760, 2003.

Davis, P; **Stanley Jr, SL.** “Breaking the species barrier: the use of mouse human chimeras to study human infectious diseases.” *Cellular Microbiology*, 2003. 5:849-860.

Stanley Jr, SL. “Antiparasitic agents.” In *Infectious Diseases*, 2nd Edition, edited by Cohen, J., and Powderly, W. London, Mosby, pp. 1941-1960, 2004.

Stanley Jr, SL. “Amebiasis.” In *Encyclopedia of Gastroenterology*. San Diego, Elsevier, pp. 52-57, 2004.

Stanley Jr, SL. “The *Entamoeba histolytica* genome: Something old, something new, something borrowed, and sex too?” *Trends in Parasitology*, 2005, Oct; 21(10):451-3.

Phillips, M; **Stanley Jr, SL** “Chemotherapy of protozoal infections.” In Goodman and Gilman’s *Pharmacological Basis of Therapeutics*, 11th Edition, edited by Lazo, JS, Parker, K, Brunton, LL, Goodman, LS and Gilman, A. New York, McGraw Hill, 2005.

Snow, M; **Stanley Jr, SL.** “Recent progress in vaccines for amebiasis.” *Archives of Medical Research*, 2006; 37:280-287.

Stanley, Jr, SL. “Vaccines for amoebiasis: barriers and opportunities.” *Parasitology*, 2006; 133:S81-86.

PATENTS:

U.S. Patent 5,130,147: *Entamoeba histolytica* Immunogenic protein and cDNA clone.

Significance: patent of the SREHP cDNA clone; recombinant SREHP is a major vaccine candidate for amebiasis, and a reagent utilized in prototype diagnostic tests.

Inventor: Samuel L. Stanley Jr., and Ellen Li.

Assignee: Washington University, St. Louis.

U.S. Patent 5,275,935: Amebic glycoconjugate and monoclonal antibody.

Significance: patent of the amebic glycoconjugate, a major surface antigen of amebae and a monoclonal antibody, CC 8.6 which recognizes this antigen. Possible uses in diagnostic kits.

Inventor: Samuel L. Stanley, Jr., and Ellen Li.

Assignee: Washington University, St. Louis.

US Patent 5,807,000: Method of screening anti-amebic compounds.

Significance: Describes the use of mutant *E. coli* strains complemented with amebic antigens to screen compounds for anti-amebic activity.

Inventor: Samuel L. Stanley, Jr.

Assignee: Washington University, St. Louis.